D/L-myo-inositol(1,2,3,4,5)pentakisphosphate | 25663-09-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: D/L-myo-inositol(1,2,3,4,5)pentakisphosphate
• 英文别名: D/L-myo-inositol(1,2,4,5,6)pentakisphosphate；penta-O-phosphono-myo-inositol；Penta-O-phosphono-myo-inosit；Penta-O-phosphono-inosit；inositol pentakisphosphate；(2-hydroxy-3,4,5,6-tetraphosphonooxycyclohexyl) dihydrogen phosphate
• CAS: 25663-09-6
• 化学式: C₆H₁₇O₂₁P₅
• 分子量: 580.057
• InChiKey: CTPQAXVNYGZUAJ-UHFFFAOYSA-N

物化性质

• 沸点：
  1106.1±75.0 °C(Predicted)
• 密度：
  2.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -9.2
• 重原子数：
  32
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  354
• 氢给体数：
  11
• 氢受体数：
  21

安全信息

• 海关编码：
  2919900090

文献信息

• [EN] TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF<br/>[FR] CONJUGUÉS CIBLÉS, PARTICULES ET PRÉPARATIONS ASSOCIÉES
  申请人：BLEND THERAPEUTICS INC

  公开号：WO2016004043A1

  公开（公告）日：2016-01-07

  Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, comprising conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.

  包括纳米颗粒和微粒子在内的粒子以及其制剂，包括将活性药剂（如治疗、预防或诊断药剂）与靶向基团通过连接剂结合的共轭物。这些设计可以提供改善活性药剂的时间空间传递和/或改善生物分布的效果。提供了制备共轭物、粒子和制剂的方法。提供了向需要的受试者（例如治疗或预防癌症或传染病）施用制剂的方法。
• Regulation of ins(3456)p4 signalling by a reversible kinase phosphatase and methods and compositions related thereto
  申请人：Shears B Stephen

  公开号：US20060035810A1

  公开（公告）日：2006-02-16

  Provided is a method of increasing 3,4,5,6-tetrakisphosphate by increasing the activity of inositol 1,3,4,5,6 pentakisphosphate 1-phosphatase, and a method of decreasing 3,4,5,6-tetrakisphosphate by decreasing the activity of inositol 1,3,4,5,6 pentakisphosphate 1-phosphatase. A method of reducing salt, fluid or mucous secretion in a subject, comprising increasing the activity of inositol 1,3,4,5,6 pentakisphosphate 1-phosphatase in the subject is provided. A method of treating a disease that is exacerbated by salt, fluid or mucous secretion is also provided, comprising increasing the activity of inositol 1,3,4,5,6 pentakisphosphate phosphatase in a subject having a disease that is exacerbated by mucous, whereby mucous secretion is reduced and the disease is treated. Also provided is method of increasing salt and fluid secretion in a subject, comprising decreasing the activity of inositol 1,3,4,5,6 pentakisphosphate 1-phosphatase in the subject. A method of treating a disease that is treated by increased salt and fluid secretion is provided, comprising decreasing the activity of inositol 1,3,4,5,6 pentakisphosphate 1-phosphatase in a subject having a disease that is treated by increased salt and fluid secretion, whereby salt and fluid secretion is increased and the disease is treated.

  提供了一种通过增加肌醇1,3,4,5,6五磷酸1-磷酸酶的活性来增加3,4,5,6四磷酸盐的方法，以及通过降低肌醇1,3,4,5,6五磷酸1-磷酸酶的活性来减少3,4,5,6四磷酸盐的方法。提供了一种在受试对象中减少盐、液体或黏液分泌的方法，包括增加受试对象中肌醇1,3,4,5,6五磷酸1-磷酸酶的活性。还提供了一种治疗因盐、液体或黏液分泌加重的疾病的方法，包括增加患有因黏液分泌加重的疾病的受试对象中肌醇1,3,4,5,6五磷酸磷酸酶的活性，从而减少黏液分泌并治疗疾病。还提供了一种在受试对象中增加盐和液体分泌的方法，包括降低受试对象中肌醇1,3,4,5,6五磷酸1-磷酸酶的活性。提供了一种治疗因增加盐和液体分泌而治疗的疾病的方法，包括降低因增加盐和液体分泌而治疗的疾病的受试对象中肌醇1,3,4,5,6五磷酸1-磷酸酶的活性，从而增加盐和液体分泌并治疗疾病。
• MICROORGANISMS AND METHODS FOR PRODUCING 2,4-PENTADIENOATE, BUTADIENE, PROPYLENE, 1,3-BUTANEDIOL AND RELATED ALCOHOLS
  申请人：Osterhout Robin E.

  公开号：US20130109064A1

  公开（公告）日：2013-05-02

  The invention provides non-naturally occurring microbial organisms containing 2,4-pentadienoate, butadiene, propylene, 1,3-butanediol, crotyl alcohol or 3-buten-1-ol pathways comprising at least one exogenous nucleic acid encoding a butadiene pathway enzyme expressed in a sufficient amount to produce 2,4-pentadienoate, butadiene, propylene, 1,3-butanediol, crotyl alcohol or 3-buten-1-ol. The invention additionally provides methods of using such microbial organisms to produce 2,4-pentadienoate, butadiene, propylene, 1,3-butanediol, crotyl alcohol or 3-buten-1-ol, by culturing a non-naturally occurring microbial organism containing 2,4-pentadienoate, butadiene, propylene, 1,3-butanediol, crotyl alcohol or 3-buten-1-ol pathways as described herein under conditions and for a sufficient period of time to produce 2,4-pentadienoate, butadiene, propylene, 1,3-butanediol, crotyl alcohol or 3-buten-1-ol.

  本发明提供了不自然存在的微生物生物体，包含2,4-戊二烯酸、丁二烯、丙烯、1,3-丁二醇、烯丙醇或3-丁烯-1-醇途径，其中包括至少一个外源核酸编码的丁二烯途径酶，在足够数量下表达以产生2,4-戊二烯酸、丁二烯、丙烯、1,3-丁二醇、烯丙醇或3-丁烯-1-醇。此外，本发明提供了使用这种微生物生物体生产2,4-戊二烯酸、丁二烯、丙烯、1,3-丁二醇、烯丙醇或3-丁烯-1-醇的方法，通过在适当的条件下培养包含2,4-戊二烯酸、丁二烯、丙烯、1,3-丁二醇、烯丙醇或3-丁烯-1-醇途径的不自然存在的微生物生物体，并在足够的时间内产生2,4-戊二烯酸、丁二烯、丙烯、1,3-丁二醇、烯丙醇或3-丁烯-1-醇。
• MICROORGANISMS AND METHODS FOR PRODUCING ALKENES
  申请人：Burk Mark J.

  公开号：US20130122563A1

  公开（公告）日：2013-05-16

  The invention provides non-naturally occurring microbial organisms containing an alkene pathway having at least one exogenous nucleic acid encoding an alkene pathway enzyme expressed in a sufficient amount to convert an alcohol to an alkene. The invention additionally provides methods of using such microbial organisms to produce an alkene, by culturing a non-naturally occurring microbial organism containing an alkene pathway as described herein under conditions and for a sufficient period of time to produce an alkene.

  本发明提供了非自然存在的微生物生物体，其含有至少一种外源核酸编码的烯烃途径酶，表达量足以将醇转化为烯烃。本发明还提供了使用这种微生物生物体生产烯烃的方法，通过在适当的条件和足够的时间下培养含有如上所述的烯烃途径的非自然存在的微生物生物体，以产生烯烃。
• Tangential flow affinity ultrafiltration
  申请人：HEMOSOL INC.

  公开号：EP0229696A1

  公开（公告）日：1987-07-22

  Biological macromolecules are separated from liquid mixtures in which they are contained, in substantially pure form, by a process involving tangential flow ultrafiltration of the liquid mixture in the presence of an affinity gel which binds selectively to the biological macromolecule to be recovered in pure form, in either the positive affinity absorption mode or the negative affinity absorption mode. Thus a mixture containing the biological macromolecule of interest, such as hemoglobin or (oxy)hemoglobin is first mixed with an affinity gel, such as agarose-ATP, which selectively binds to the hemoglobin or (oxy)hemoglobin and then the liquid is subjected to tangential flow ultrafiltration, so that all components of the mixture except the gel-bond hemoglobin pass through the filter. In a second stage, the gel-bond hemoglobin is treated with a salt solution to displace the hemoglobin from the gel, and then the mixture is passed again over a tangential flow ultrafiltration membrance, so that the pure hemoglobin is separated from the gel, and collected in filtrate. The affinity gel which remains in retentate can then be regenerated and re-used.

  生物大分子可以通过切向流超滤的方法从液体混合物中分离出来，液体混合物中的生物大分子基本上是纯的，在亲和凝胶存在的情况下，亲和凝胶选择性地与要以纯形式回收的生物大分子结合，亲和吸收模式可以是正亲和吸收模式，也可以是负亲和吸收模式。因此，首先将含有相关生物大分子（如血红蛋白或（氧）血红蛋白）的混合物与选择性地与血红蛋白或（氧）血红蛋白结合的亲和凝胶（如琼脂糖-ATP）混合，然后对液体进行切向流超滤，使混合物中除凝胶结合血红蛋白以外的所有成分都通过过滤器。在第二阶段，用盐溶液处理凝胶键合血红蛋白，将血红蛋白从凝胶中置换出来，然后将混合物再次通过切向流超滤膜，使纯血红蛋白从凝胶中分离出来，并收集到滤液中。残留在滤液中的亲和凝胶可以再生并再次使用。